CERo Therapeutics Holdings (CERo Therapeutics Holdings) Current Accrued Expense : $0.08 Mil (As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Current Accrued Expense?

CERo Therapeutics Holdings's Current Accrued Expense for the quarter that ended in Dec. 2022 was $0.08 Mil.

CERo Therapeutics Holdings's quarterly Current Accrued Expense increased from . 20 ($0.00 Mil) to Dec. 2021 ($0.03 Mil) and increased from Dec. 2021 ($0.03 Mil) to Dec. 2022 ($0.08 Mil).

CERo Therapeutics Holdings's annual Current Accrued Expense increased from . 20 ($0.00 Mil) to Dec. 2021 ($0.03 Mil) and increased from Dec. 2021 ($0.03 Mil) to Dec. 2022 ($0.08 Mil).

CERo Therapeutics Holdings Current Accrued Expense Historical Data

The historical data trend for CERo Therapeutics Holdings's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Current Accrued Expense Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Current Accrued Expense

0.03

0.08

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Current Accrued Expense	0.03	0.08

CERo Therapeutics Holdings Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

CERo Therapeutics Holdings Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024